Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.49
-0.05 (-0.90%)
At close: May 22, 2026, 4:00 PM EDT
5.51
+0.02 (0.36%)
After-hours: May 22, 2026, 7:58 PM EDT
Taysha Gene Therapies Market Cap
Taysha Gene Therapies has a market cap or net worth of $1.58 billion as of May 22, 2026. Its market cap has increased by 304.93% in one year.
Market Cap
1.58B
Enterprise Value
1.37B
1-Year Change
304.93%
Ranking
Category
Stock Price
$5.49
Market Cap Chart
Since the IPO on September 24, 2020, Taysha Gene Therapies's market cap has increased from $690.43M to $1.58B, an increase of 128.50%. That is a compound annual growth rate of 15.73%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 21, 2026 | 1.59B | 5.67% |
| Dec 31, 2025 | 1.51B | 324.92% |
| Dec 31, 2024 | 354.55M | 7.14% |
| Dec 29, 2023 | 330.92M | 134.50% |
| Dec 30, 2022 | 141.12M | -68.52% |
| Dec 31, 2021 | 448.22M | -55.28% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Sep 24, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Iovance Biotherapeutics | 1.65B |
| Recursion Pharmaceuticals | 1.65B |
| Innoviva | 1.64B |
| Inhibrx Biosciences | 1.62B |
| Monte Rosa Therapeutics | 1.59B |
| AtaiBeckley | 1.59B |
| AbCellera Biologics | 1.57B |
| Ardelyx | 1.57B |